Related Experiment Video
Updated: May 23, 2026
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Targeting NRAS in melanoma
Fergal C Kelleher1, Grant A McArthur
1Division of Cancer Medicine, Peter MacCallum Cancer Centre, Victoria, Australia.
Abstract:
Cutaneous melanomas have mutations in the NRAS GTPase in 15% of cases. Compared to melanomas with BRAF mutations, or melanomas "wild-type" for BRAF and NRAS, melanomas with NRAS mutations are more likely to be thicker tumors and to have a higher mitotic rate. Preclinical studies indicate that melanoma cells with NRAS mutations are dependent on NRAS for survival and proliferation, making NRAS an attractive therapeutic target in melanoma. However, to date, therapeutic strategies for NRAS mutant melanomas have not been realized. Promising strategies to target NRAS include targeting the membrane localization of NRAS or reducing expression through the use of therapeutic small interfering RNAs. Finally, use of inhibitors to target downstream signaling through mitogen-activated protein kinase kinase and phosphatidylinositol 3-OH kinase or AKT are now entering clinical trials, and if these combinations can be safely delivered at sufficient dose to inhibit the targets, there is significant potential to target NRAS mutant melanoma.
Insights
NRAS mutations in melanoma are linked to thicker tumors and faster growth. Targeting NRAS offers a promising therapeutic strategy for this aggressive cancer, with new clinical trials exploring combination therapies.
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Cutaneous melanomas frequently harbor NRAS GTPase mutations (15% of cases).
- NRAS-mutant melanomas exhibit increased tumor thickness and mitotic rate compared to BRAF-mutant or wild-type melanomas.
- NRAS is crucial for melanoma cell survival and proliferation, presenting it as a key therapeutic target.
Purpose of the Study:
- To review the therapeutic landscape for NRAS-mutant melanoma.
- To highlight emerging strategies targeting NRAS and its downstream pathways.
Main Methods:
- Review of preclinical studies on NRAS-mutant melanoma.
- Analysis of current therapeutic strategies and clinical trial data.
Main Results:
- NRAS mutations are associated with more aggressive melanoma phenotypes.
- Therapeutic strategies targeting NRAS, including membrane localization inhibition and small interfering RNA (siRNA) approaches, are under investigation.
- Clinical trials are evaluating downstream signaling inhibitors (MAPKK, PI3K/AKT).
Conclusions:
- NRAS-mutant melanoma presents a significant therapeutic challenge.
- Targeting NRAS directly or its downstream pathways holds potential for effective treatment.
- Successful clinical application hinges on safe and effective delivery of combination therapies.
Related Concept Videos
02:23Abnormal Proliferation
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...